WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its
fourth quarter 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets.
In connection with the earnings release, Syndax's management team will host a conference call and live audio
webcast at 4:30 p.m. ET on Thursday, March 2, 2017, to discuss the Company's financial results and provide a general business
update.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the
Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the
following:
Conference ID: 63366789
Domestic Dial-in Number: 1-855-251-6663
International Dial-in Number: 281-542-4259
Live webcast: http://edge.media-server.com/m/p/6txfuwhh
For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the
Investors section of the Company's website, www.syndax.com.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company focused on developing an innovative pipeline of combination therapies in
multiple cancer indications. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA
following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial
for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Syndax is developing
entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal
antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being
evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and
melanoma; with Genentech, Inc. for TNBC; and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is
being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers.
For more information on Syndax, please visit www.syndax.com.
Syndax’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "believe" and similar expressions (as well as
other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press
release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these
forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements
about the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's
product candidates, and the potential use of SNDX-6352 to treat various cancer indications. Many factors may cause differences
between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or
clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing
competition, changes in the regulatory environment, failure of Syndax's collaborators to support or advance collaborations or
product candidates and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from
those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S.
Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax
assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new
information becomes available.
Investor Contact: Heather Savelle Argot Partners heather@argotpartners.com Tel 646.395.3734 Media Contact: Eliza Schleifstein Argot Partners eliza@argotpartners.com Tel 917.763.8106
